TY - JOUR
T1 - Hepatitis B- and C-related hepatocellular carcinomas yield different clinical features and prognosis
AU - Chen, Chien Hung
AU - Huang, Guan Tarn
AU - Yang, Pei Ming
AU - Chen, Pei Jer
AU - Lai, Ming Yang
AU - Chen, Ding Shinn
AU - Wang, Jung Der
AU - Sheu, Jin Chuan
N1 - Funding Information:
This study was financially supported by the grants from the Department of Health, Taiwan (DOH90-HP-1002), the National Health Research Institute, Taiwan (NHRI-EX94-9204PP), and the Liver Disease Prevention & Treatment Research Foundation, Taiwan. We are indebted to our colleagues at the Cancer Registry, Office of Medical Record, NTUH, for their excellent work in the cancer registry system and to the physicians for their care of the patients.
PY - 2006/10
Y1 - 2006/10
N2 - The purpose of this study was to compare the clinical features and survival in patients with hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) and hepatitis C virus-related hepatocellular carcinoma (HCV-HCC). A total of 2820 HCC patients were included. The mean age of HBV-HCC patients was 52.5 ± 13.4 years, while it was 64.8 ± 8.7 years in HCV-HCC patients. The male/female ratio was 7.8 in HBV-HCC, while it was 1.7 in HCV-HCC. The mean α-fetoprotein level in HBV-HCC was 11,661 ± 22,805 ng/mL, while it was 5079 ± 15,005 ng/mL in HCV-HCC. The mean tumour size was 6.4 ± 4.1 cm in HBV-HCC, while it was 4.6 ± 3.1 cm in HCV-HCC. The median survival was 11.1 months in HBV-HCC, while it was 23.9 months in HCV-HCC. Compared with HBV-HCC patients, HCV-HCC patients were older, had a lower male/female ratio, lower white blood cell count, lower serum albumin level, higher serum ALT level, lower serum α-fetoprotein level, smaller tumour size and survived longer.
AB - The purpose of this study was to compare the clinical features and survival in patients with hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) and hepatitis C virus-related hepatocellular carcinoma (HCV-HCC). A total of 2820 HCC patients were included. The mean age of HBV-HCC patients was 52.5 ± 13.4 years, while it was 64.8 ± 8.7 years in HCV-HCC patients. The male/female ratio was 7.8 in HBV-HCC, while it was 1.7 in HCV-HCC. The mean α-fetoprotein level in HBV-HCC was 11,661 ± 22,805 ng/mL, while it was 5079 ± 15,005 ng/mL in HCV-HCC. The mean tumour size was 6.4 ± 4.1 cm in HBV-HCC, while it was 4.6 ± 3.1 cm in HCV-HCC. The median survival was 11.1 months in HBV-HCC, while it was 23.9 months in HCV-HCC. Compared with HBV-HCC patients, HCV-HCC patients were older, had a lower male/female ratio, lower white blood cell count, lower serum albumin level, higher serum ALT level, lower serum α-fetoprotein level, smaller tumour size and survived longer.
UR - http://www.scopus.com/inward/record.url?scp=84983719238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84983719238&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2006.06.007
DO - 10.1016/j.ejca.2006.06.007
M3 - Article
C2 - 16920352
AN - SCOPUS:84983719238
SN - 0959-8049
VL - 42
SP - 2524
EP - 2529
JO - European Journal of Cancer
JF - European Journal of Cancer
IS - 15
ER -